Elanco Animal Health (ELAN) Tops Q3 EPS by 4c, Revenues Miss; Offers FY18 EPS Outlook Above Consensus,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Elanco Animal Health (ELAN) Announces Collaboration Agreement with Novozymes
November 2, 2018 6:53 AM EDTElanco Animal Health Incorporated (NYSE: ELAN), announced today a new global R&D collaboration with Novozymes A/S (OMX: NZYM B), the world leader in biological solutions, to develop nutritional health products for beef cattle and dairy cows globally.
The effort will leverage Novozymes leading discovery and development programs, and together the companies will collaborate to develop a R&D pipeline and commercialize products in the next decade.
Nutritional health is an exciting platform that will define the next generation of feed additives to improve... More
